kaiser permanente and glp 1 glp-1 kaiser permanente semaglutide coverage 📌 Starting January 1, 2025, Kaiser Permanente will be making adjustments to GLP-1 Weight-Loss Drug Demonstration Begins

Common consequences include: Weight gain or difficulty losing weight Fatigue and low energy Insulin resistance Constipation, dry skin, and cold intolerance Depression or brain fog Notably, thyroid dysfunction can mask or worsen metabolic conditions like obesity, insulin resistance, and prediabetesthe very issues GLP-1 drugs aim to address

Saxenda: Dual Action and Daily Dosing Mounjaro: This is a newer dual-action medication

Symptoms of B12 deficiency include persistent fatigue, weakness, brain fog, mood changes, numbness or tingling in hands and feet, and difficulty concentrating

Similarly, Priya S

Plan ahead by requesting a travel letter from your pharmacy confirming the medication and its storage needs

crassa (Borum and Broquist, 1977)